Issue 180

Psychedelics are here, now: preparing psychiatry for a psychedelic future

2024 set off to a strong start for psychedelic medicines with several watershed moments that are setting the stage for the sector’s acceleration – and the positive developments for the industry are continuing.

Recent years have seen an increasing amount of scientific evidence pointing to the potential of psychedelics as treatments for mental health conditions such as anxiety, depression, and PTSD. So far, this evidence has led countries such as Australia, Canada, and the US to allow special access to these medicines for select patients.

These developments may see psychedelics become part of psychiatric practice in the near future.

In a new article published in the British Journal of Psychiatry, researchers have emphasised the need for the psychiatry profession to prepare for a psychedelic future, and discuss how health systems might respond to these developments.

“Given the rapidly emerging body of evidence of efficacy for psilocybin and MDMA, people’s great need for innovative treatments and the move towards approval in some countries before licences are awarded, it seems likely that these two drugs will become a part of psychiatric practice for many in the foreseeable future. The psychiatry profession and practising psychiatrists need to prepare for this.”



Reuters reports that shares of Atai Life Sciences surged by 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.

“The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering (IPO) on Thursday.”

Read More


Science Alert reports that psilocybin has promising potential as a treatment for the eating disorder anorexia nervosa, according to new research that looked at its effects.

“Administered in the right way, experts are hopeful that the way psilocybin activates serotonin receptors in the brain – causing expanded and altered states of consciousness – might shift mental blocks that have developed around eating.”

Read More


The Irish Times explores if microdosing with psychedelics could help treat depression.

A first of its kind imaging study has provided insights into how the brain works on psychedelic drugs.

Esquire explores why psilocybin mushrooms could help with ADHD through a case study.

Police officers from the UK are heading to Peru to try ayahuasca for work-related trauma, reports the Daily Star.


A push to legalise psychedelics in Massachusetts has been met with caution, reports Greenfield Recorder.

A new Assembly Bill in New York is seeking to legalise psilocybin service centers, reports High Times.


Psilera is set to unveil new data on its lead clinical asset at the BIO International Conference on June 5th.

The Health Research Ethics Board of Alberta has approved ATMA’s Phase II Psilocybin Clinical Trial with group and individual therapy settings.

Novotech has entered into an MOU with a New Zealand-based Psychedelics Research Centre.

Reunion Neuroscience has announced results from preclinical studies on the potential of its psilocybin-like drug for Depressive Disorders.


A new report from Deloitte has revealed that the total annual cost of poor mental health to employers has increased by 25% since 2019, amounting to an estimated £53-56 bn between 2020-21.

A report on mental health from Boehringer Ingelheim has revealed barriers and potential solutions to meet the growing, unmet demand for mental health services worldwide.